Monrovia, CA (PressExposure) October 22, 2013 -- Leroy Hood, President of the Institute for Systems Biology, will give a keynote presentation on "Systems Approaches to Disease: Emerging Technologies and Novel Strategies including Blood Diagnostics" at the Biomarker Summit 2014 on March 19-21, 2014 in San Diego, CA.
Systems medicine has provided striking new insights into the dynamics of disease; it has pioneered the development of new technologies, the translation of big data and a focus on personalized data clouds; and it has pushed the creation of new strategies for dealing with disease. Dr. Hood's presentation will discuss in particular how these approaches are employed for blood diagnostics using several examples--lung cancer and PTSD. He will discuss each of these areas and conclude with the point that systems medicine has reached a tipping point that is already changing the practice of healthcare.
Dr. Hood will also speak on the convergence of systems medicine, big data and patient-activated social networks that have led to a medicine that is predictive, preventive, personalized and participatory--P4 medicine. He will contrast P4 medicine with the current evidence-based medicine--and illustrate how profoundly different these two approaches are. He will then end by also discussing how P4 will profoundly impact society.
Dr. Leroy Hood is a pioneer in the systems approach to biology and medicine. His research has focused on the study of molecular immunology, biotechnology and genomics. A pillar in the biotechnology field, Dr. Hood has played a role in founding more than fourteen biotechnology companies, including Amgen, Applied Biosystems, Darwin, The Accelerator and Integrated Diagnostics. He is a member of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine. Dr. Hood has published more than 700 peer reviewed articles and currently holds 36 patents.
The Biomarker Summit 2014 brings together experts from industry, academia and non-profit organizations to discuss the latest developments in the biomarker and diagnostics field. The summit will consist of three parallel tracks focused on different therapeutics areas:
1) 7th Oncology Biomarkers
2) 3rd Neurological Biomarkers
3) 3rd Inflammatory & Immunological Biomarkers
For more information, please visit http://www.gtcbio.com/biomarkers